Concerns about the discontinuation of triamcinolone acetonide in the management of keloid and hypertrophic scars.
Where this comes from
- Record sourced from PubMed, PMID 40669115.
- Also identified by DOI 10.1016/j.bjps.2025.07.009.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Triamcinolone acetonide (TAC), a synthetic glucocorticoid, is commonly administered as an intralesional injection for patients who present in our clinics with keloid or hypertrophic scars (HTS). The use of TAC (i.e. Adcortyl® or Kenalog® supplied by Bristol-Myers-Squibb) for this purpose is also supported by many studies.<sup>1</sup> It therefore comes with great disappointment to learn the decision from Department of Health and Social Care to withdraw the license for use of Adcortyl® and Kenalog® in the UK, especially as there are limited studies evaluating the suitability of alternatives.<sup>1,3</sup> However, we encourage the investigation into the potential therapeutic effects of benzyl alcohol (15mg/ml), an excipient in Adcortyl® and Kenalog®, in the treatment of keloids and HTS in the future.<sup>5</sup>.
Medical subject headings
- Keloid
- Triamcinolone Acetonide
- Cicatrix, Hypertrophic
- Glucocorticoids